Sign up to save your podcasts
Or
Share New and emerging therapies in gMG: going upstream, T-cell and B-cell targeted therapies
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
New and emerging therapies in gMG: going upstream, T-cell and B-cell targeted therapies
Awareness, Advances, Action: Optimizing Outcomes for Patients with Generalized Myasthenia Gravis
In the second half of this two-part episode, Dr. Kelly Gwathmey, MD, and Dr. Pushpa Narayanaswami, MD, FAAN, discuss the importance of understanding the evolving therapeutic landscape for gMG. They explore the latest B-cell and T-cell targeted therapies, including monoclonal antibodies, CAR-T cell approaches, and small molecule inhibitors, with insights into clinical trial data, mechanisms of action, and real-world considerations for patient-centered care.
To access the other episodes in the gMG disease dialogues series and earn CME credits, visit https://myastheniagravis.ime.springerhealthcare.com/advances-gmg-disease-dialogues-series/. The series features expert discussion on the new and emerging therapies for gMG, practical insights for integrating treatment advances, and the importance of multidisciplinary collaboration to optimize patient care.
Earn free CME credits- visit https://myastheniagravis.ime.springerhealthcare.com/ to check out the complete accredited program on optimizing patient outcomes in gMG.
Intended for healthcare professionals only.
Supported by an independent educational grant from Merck KGaA, Darmstadt, Germany and UCB Inc.
© 2025 Springer Healthcare LLC. Springer Health+ IME is part of Springer Nature. All rights reserved.
View all episodes
By Springer Health+ IMEAwareness, Advances, Action: Optimizing Outcomes for Patients with Generalized Myasthenia Gravis
In the second half of this two-part episode, Dr. Kelly Gwathmey, MD, and Dr. Pushpa Narayanaswami, MD, FAAN, discuss the importance of understanding the evolving therapeutic landscape for gMG. They explore the latest B-cell and T-cell targeted therapies, including monoclonal antibodies, CAR-T cell approaches, and small molecule inhibitors, with insights into clinical trial data, mechanisms of action, and real-world considerations for patient-centered care.
To access the other episodes in the gMG disease dialogues series and earn CME credits, visit https://myastheniagravis.ime.springerhealthcare.com/advances-gmg-disease-dialogues-series/. The series features expert discussion on the new and emerging therapies for gMG, practical insights for integrating treatment advances, and the importance of multidisciplinary collaboration to optimize patient care.
Earn free CME credits- visit https://myastheniagravis.ime.springerhealthcare.com/ to check out the complete accredited program on optimizing patient outcomes in gMG.
Intended for healthcare professionals only.
Supported by an independent educational grant from Merck KGaA, Darmstadt, Germany and UCB Inc.
© 2025 Springer Healthcare LLC. Springer Health+ IME is part of Springer Nature. All rights reserved.